BOS127238, a novel, highly selective RET inhibitor, was associated with a manageable safety profile and preliminary efficacy in a phase I study in RET-altered solid tumors.
Results of this preplanned interim analysis demonstrated significantly improved DFS with adjuvant atezolizumab in patients with stage II-IIIA NSCLC, particularly for individuals with PD-L1–positive tumors.
Longer-term results from PACIFIC show sustained OS and PFS benefit—with 5-year OS and PFS rates of 42.9% and 33.1%, respectively—with concurrent CRT followed by 1 year of durvalumab.
Pembrolizumab + concurrent CRT followed by pembrolizumab consolidation conferred encouraging antitumor activity regardless of nonsquamous or squamous histology and PD-L1 expression levels.
First-line nivolumab plus ipilimumab with chemotherapy continued to provide durable clinical benefit in patients with advanced NSCLC regardless of PD-L1 expression with extended follow-up.
Results of this retrospective exploratory analysis suggest that chemo-IO regimens may improve OS and PFS compared with IO alone in most patients with previously untreated advanced NSCLC and tumor PD-L1 expression 1% to 49%.
Clinical benefit of sotorasib in patients with previously treated KRAS p.G12C–mutated NSCLC observed across subgroups prespecified by baseline characteristics and in exploratory analyses of molecularly defined subgroups.
Multivariable regression analyses of deidentified health record data showed that Black patients with NSCLC were less likely to receive NGS-based genetic testing or enroll on clinical trials than White patients.
Amivantamab plus lazertinib achieved an ORR of 36% in chemotherapy-naive patients with disease progression on first-line osimertinib.
Updated phase I results with extended follow-up show antitumor activity of patritumab deruxtecan in patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC across various EGFR TKI resistance mechanisms and regardless of prior therapy or presence of CNS metastases.
First-line nivolumab plus ipilimumab continued to provide durable clinical benefit in patients with advanced NSCLC regardless of PD-L1 expression level with extended follow-up.
Phase I results from TROPION-PanTumor01 suggest durable antitumor activity and a manageable safety profile with datopotamab deruxtecan in patients with previously treated advanced NSCLC.